Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG) granted Valeant Pharmaceuticals International Inc. (NYSE: VRX) exclusive worldwide commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437. Shares of Eyegate Pharmaceuticals leaped $2.06 to close at $3.70 while Valeant stock added 36 cents to close at $16.40.
Eyegate Pharmaceuticals grants Valeant exclusive rights
February 21, 2017 at 16:51 PM EST
